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Summary Flexible heteroarotinoids (Flex-Hets) com-
pounds regulate growth, differentiation and apoptosis in
cancer cells. The hypothesis of this study was that the lead
Flex-Het, SHetA2, inhibits angiogenesis by blocking
cytokine release from cancer cells. SHetA2 altered secretion
of thrombospondin-4 (TSP-4), vascular endothelial growth
factor A (VEGF) and fibroblast growth factor (bFGF)
proteins from normal and cancerous ovarian and renal
cultures. Thymidine phosphorylase (TP) expression was
inhibited in cancer, but not normal cultures. Endothelial tube
formation was stimulated by conditioned media from cancer
but not normal cultures, and SHetA2 reduced secretion of
this angiogenic activity. SHetA2 directly inhibited endothe-
lial cell tube formation and proliferation through G1 cell
cycle arrest, but not apoptosis. Recombinant TP reversed
SHetA2 anti-angiogenic activity. SHetA2 inhibition of in
vivo angiogenesis was observed in Caki-1 renal cancer
xenografts. In conclusion, SHetA2 inhibits angiogenesis
through alteration of angiogenic factor secretion by cancer
cells and through direct effects on endothelial cells.
Keywords Angiogenesis.Vascularendothelialgrowth
factor.Thymidine phosphorylase.Basic fibroblast
growth factor.Thrombospondin4.Heteroarotinoid
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Ovarian and renal cancers are two of the most lethal cancers
with the poor mortality linked to late stage of diagnosis and
to poor response to chemotherapy and development of
resistance [1]. Due to the highly vascularized nature of
these cancers, anti-angiogenic strategies are actively being
pursued to improve the dismal patient outcome [2, 3].
Therapeutic strategies that target the neovasculature of
tumors have shown modest results [4]. Issues of these anti-
angiogenesis drugs with regard to toxicity and avoiding
interference with standard chemotherapy are currently
under intense investigation. Therapeutic strategies that
target both cancer and endothelial cells within a tumor will
be effective if they can be administered in a manner that
does not shut down the neovasculature before the drug can
access and kill the cancer cells. Drugs that target the
neovasculature without affecting the cancer cells may be
able to prevent growth and metastases of the cancer, but
may not be able to completely eliminate the cancer, unless
the population of cancer cells has a sufficiently high
apoptosis rate to completely overwhelm the proliferation
rate.
Endothelial cells that form the neovasculature of tumors
share many signaling pathways with cancer cells and some
established anti-cancer drugs, such as taxol, have been
found to have anti-angiogenesis activity [5]. Thus, in the
development of new anti-cancer drugs, evaluation of
potential anti-angiogenesis effects should be taken into
consideration for guidance in optimizing the strategy for
clinical administration in order to take advantage of any
anti-angiogenic effects and take into consideration potential
toxicities associated with anti-angiogenesis activity.
Heteroarotinoids (Hets) represent a novel class of small
molecule drugs with promising anti-cancer activity that
were originally derived from the arotinoid class of retinoids
by insertion of a heteroatom into the cyclic ring of
arotinoids. Arotinoids proved to be 1,000-fold more toxic
than the natural retinoid, all-trans retinoic acid (t-RA),
while the heteroatom was found to decrease the toxicity of
Hets 1,000-fold back to similar levels as t-RA [6]. Through
structure activity relationship studies, a series of Hets that
exhibit promising in vivo anti-cancer activity were devel-
oped [6–10]. A more potent class of Hets were developed by
substitution of the two atom linker with a more flexible urea
or thiourea linker to produce Flexible Hets (Flex-Hets).
Similar to arotinoids and conventional Hets, Flex-Hets
inhibited cell growth and induced differentiation, but in
contrast to the parent compounds, were potent inducers of
apoptosis through a mechanism independent of the retinoic
acid receptors [8, 11]. The lack of receptor activation is
consistent with the lack of skin irritancy and teratogenicity
of Flex-Hets [12, 13]. Studies using matching sets of cancer
cell lines and normal cells derived from the same organ
(ovary, kidney and endometrium), demonstrated that nor-
mal cells are much more resistant to Flex-Het apoptosis in
comparison to the corresponding cancer cell lines (Liu et al.
2008, in preparation) [14, 15].
The Flex-Het containing a sulfur heteroatom, a thiourea
linker and an NO2 component, SHetA2 [(4-nitrophenyl)
amino][2,2,4,4-tetramethylthiochroman-6-yl)amino]meth-
ane-thione], was chosen as the lead based on the greatest
levels of efficacy and potency of growth inhibition activity
across all cell lines tested, while retaining the differential
reduced effect on normal cultures. The differential effect of
SHetA2 on cancer versus normal cells was associated with
direct targeting of mitochondria and decrease of Bcl-2 and
Bcl-xl proteins in cancer cells with little effect on normal
cells [15]. Promising in vivo anticancer activity [12] and
the ability to inhibit the development of cancer in an
organotypic model [16] prompted the acceptance of
SHetA2 into the National Cancer Institute’s RAID (Rapid
Access to Intervention Development, NSC 72689) and
RAPID (Rapid Access to Preventive Intervention Develop-
ment) programs for preclinical development as a therapeu-
tic and chemopreventive agent for cancer, respectively.
Microarray analysis of ovarian cancer organotypic
cultures identified 44 genes to be significantly regulated
by SHetA2. One of the down-regulated genes, Thymidine
Phosphorylase (TP), also known as platelet-derived endo-
thelial cell growth factor (PD-ECGF), is a known anti-
angiogenic growth factor. The TP enzyme is involved in the
nucleotide salvage pathway important for cell proliferation
by converting thymidine to thymine and 2-deoxy-D-ribose-
1-phosphate. The latter metabolite and subsequent metab-
olite 2-deoxy-D-ribose have been shown to be responsible
for the angiogenic activity of TP [17], while 2-deoxy-
L-ribose and the TP enzyme activity inhibitor CIMU (5-
chloro-6(1-imidazolylmethyl)uracil) could prevent the
angiogenic stimulating activity of TP [17]. Administra-
tion of TP was demonstrated to enhance tumor progres-
sion and to protect cells against hypoxia induced apoptosis
[18]. Higher levels of TP expression were observed in a
variety of tumor types in comparison to surrounding nor-
mal tissues and appeared to be correlated with poor
patient prognosis [19].
Another of the SHetA2 down-regulated genes that has
potential angiogenesis regulating activity was thrombo-
spondin 4 (TSP-4). Initially, TSP-4 was not considered to
be anti-angiogenic because it lacks the protein structures in
TSP-1 called type 1 repeats that are responsible for the anti-
angiogenesis mechanism [20, 21]. TSP-4 may be anti-
angiogenic however, in that it contains the type III repeats
found in TSP-1 that have recently been reported to inhibit
binding of FGF-2 to endothelial cells, a process that leads
to endothelial cell proliferation in vitro [22].
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exhibited anti-angiogenic activity. It was hypothesized that
altered expression of TP and TSP-4, in addition to the
well-characterised angiogenic cytokines vascular endothe-
lial cell growth factor (VEGF) and basic fibroblast growth
factor (bFGF) would upset the balance of pro- and anti-
angiogenic factors secreted by cancer cells resulting a net
alteration in angiogenesis regulating activity. In addition,
it was hypothesized that SHetA2 would directly inhibit
growth and differentiation of endothelial cells, which
would interfere with their ability to form and maintain
vascular structures.
Materials and methods
Cell lines and drugs
The A2780 (Michael Birrer, National Cancer Institute) and
OVCAR-3 (ATCC) ovarian cancer cell lines were main-
tained in RPMI media supplemented with 1 mM sodium
pyruvate, 10 mM HEPES, 10% fetal bovine serum (FBS)
and antibiotic/antimycotic. IOSE-80 (Michael Birrer) cells
were cultured in IOSE Growth Media consisting of 1:1
Medium 199:MCDB105 supplemented with 15% FBS.
McCoy’s medium supplemented with 10% FBS, antibiotic
and antimycotic was used to culture the Caki-1 cell line
(ATCC) derived from a human skin metastatic lesion of a
renal clear cell carcinoma and the HK-2 cell line (human
kidney 2 from ATCC), which is a proximal tubular cell
(PTC) line derived from normal kidney and immortalized
with human papillomavirus 16 (HPV-16) E6/E7 genes.
Human umbilical vein endothelial cells (HUVEC) primary
cultures and the EAhy.926 cells (Cora-Jean S. Edgell,
Ph.D., University of North Carolina), a line that was
generated by fusing HUVEC with a carcinoma cell line
[23], were maintained in EBM-2 media supplemented with
2% FBS (Cambrex Bio Science). SHetA2 was synthesized
by K. Darrell Berlin (Oklahoma State University) as
previously described [14], dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 0.01 M and stored at −80°C.
All manipulations were performed in subdued lighting to
avoid photo-oxidation of the drug. Recombinant Thymidine
Phosphorylase (R&D Systems) was dissolved in Phosphate
Buffered Saline at a concentration of 10 μg/mL.
Microarray analysis of organotypic cultures
Organotypic cultures of A2780 ovarian cancer cells were
prepared as previously described [8]. Briefly, cells were
plated inside and on top of collagen gels and allowed to
grow suspended in a tissue culture insert with 8 μ pores
for 1 week to generate tissue-like architecture. A final
concentration of 1 μM SHetA2 or the same volume of
solvent (DMSO) were then administered to nine replicate
cultures for each treatment group. Media and drug were
replenished on a schedule of every Monday, Wednesday
and Friday for 2 weeks. One set of the treated and untreated
cultures was fixed in formalin, embedded in paraffin. Five
micron sections were stained with hematoxylin and eosin
(H&E) for histologic evaluation (S.L.). The remaining
cultures were treated with 0.1% collagenase and the
released cells were pelleted and frozen at −80°C.
RNAwas isolated from four replicate frozen cell pellets each
of untreated and treated cultures using the RNAeasy kit
(Qiagen, Valencia CA) in combination with the Qiagen
shredder. RNA was quantified by determining the optical
density (OD) at 260 and 280 nm and all exhibited OD 260/280
ratios1.9orgreater.The integrity oftheRNAwasconfirmedby
gel electrophoresis prior to use in microarray and rt-PCR
analysis. The microarrays were printed at Microarray Research
Facility of Oklahoma Medical Research Foundation from
Human Genome Oligo Set Version 2.1 (QIAGEN Operon,
Alameda, CA) according to manufacturer’s instruction. This
70-mers oligo set contains 21,329 oligonucleotides. The oligos
were derived from the UniGene and RefSeq databases. The
details of microarray slides preparation was described in Jarvis
et al. (2004). Cy3-labeled cDNA molecules were synthesized
from 10 μg of RNA using CyScribe cDNA Post Labeling Kit
(Amersham, Piscataway, NJ). cDNA was added to Chi-
pHybe™ hybridization buffer (Ventana Medical Systems,
Tucson, AR) containing Cot-1 DNA (0.5 mg/mL final
concentration), yeast tRNA(0.2 mg/mL), and poly(dA)40–60
(0.4 mg/mL). Hybridization was performed on a Ventana
Discovery system for 6 h at 42°C. Microarrays were washed
to a final stringency of 0.1x SSC, and then scanned using a
dual-color laser instrument (Agilent Biotechnologies, Palo
Alto, CA). Fluorescent intensity was measured by Imagene™
software (BioDiscovery, Marina del Rey, CA).
Data normalization and robust regression was conducted
as described in Dozmorov and Centola [24]. Briefly in these
two steps: (1) the first step was conducted to correct the non-
specific binding of background for individual slide. This
procedure is based on the fact that spot intensities from genes
not expressed by the samples of interest constitute noise and
are therefore normally distributed. The mean (S0) and
standard deviation (SD0) of these non-expressed genes were
calculated using an iterative nonlinear curve fitting procedure
and used as background parameters for normalization using
the formula S′=(S−S0)/SD0. After the first step, the normal
distributed background signal for nonexpressed genes has a
mean of 0 and standard deviation (SD) of 1; (2) The second
step is then performed using genes significantly expressed
above background (>3 SD above background) to correct
overall variations between slides using a robust regression
procedure based on the observation that the expression levels
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From the normalized data, a “reference group” was then
establish as previously described to provide a baseline
estimate of the variance derived from technical variation
and biological stochastic processes present among samples
[25]. Only genes whose differences between treated and
untreated samples above the differences present in the
“reference group” were considered to be truly differentially
expressed and used to select genes for validation.
Relative real time reverse transcriptase polymerase chain
reaction
Monolayer cultures were treated with a range of SHetA2
concentrations or DMSO control for a range of treatment
times. Cells were lysed in RNA isolation buffer and RNA
isolated as described above was evaluated in triplicate
reactions using validated TaqMan primers (Applied Bio-
systems) specific for the test TP, TSP-4, VEGF and bFGF
genes and the control 18S genes according to manufac-
turers instructions. The delta ct method was used to
normalize the expression of each test gene to the housekeep-
ing 18S gene and to determine the relative expression of
the test genes at each dosage or time point in comparison to
the solvent only control cultures [26]. Experiments were
repeated with RNA isolated from independent sets of
treated cultures.
Measurement of SHetA2 effects of VEGF, bFGF
and growth
The effects of a range of SHetA2 concentrations on growth
and secretion of VEGF and bFGF in A2780 ovarian cancer
cells and D1 normal endometrial cultures were evaluated in
parallel. Cells were plated into 96-well plates in 50 μL/well
at a concentration of 1,000 cells/well and incubated
overnight. The next day, 50 μL of solutions containing
2X concentration of SHetA2 in growth media were added
to the relevant wells to achieve the desired concentration
range of 2, 4, 6, 8 and 10 μM SHetA2 final concentrations
in triplicate. The same final volume of DMSO achieved in
these treatments was administered to the untreated controls.
After 72 h of treatment, aliquots of the conditioned media
were removed and immediately stored at −80°C for VEGF-
A and bFGF measurements. The amount of cells remaining
in each well was measured using the CellTiter 96 Aqueous
One Solution Cell Proliferation Assay (Promega) to
confirm that effectiveness of the drug in each experiment
Western blot analysis
Cell cultures were harvested with a cell scraper, washed
once with PBS and pelleted by centrifugation. The M-PER
Mammalian Protein Extraction Reagent (Pierce) and prote-
ase inhibitor cocktail (Sigma) were used to extract proteins.
Xenograft frozen samples were homogenized in RIPA
buffer to extract proteins and cell debris was removed by
centrifugation. Concentrations of the protein extracts were
determined using PIERCE BCA protein assay kit. Proteins
(100 μg) were separated by 10% SDS-polyacrylamide gel,
electroblotted onto nitrocellulose membranes and then
blocked with 5% nonfat milk in 0.1% Tween 20-TBS for
2 h at room temperature. The membranes were immuno-
blotted with an anti-TP goat polyclonal antibody. After
further washing, the blots were incubated with donkey-anti-
goat secondary antibody. Antibody binding was detected
with the Western Blotting Luminol Reagent (Santa Cruz
Biotechnology). Membranes were stripped and re-probed
with mouse polyclonal GAPDH or β-actin as protein
loading controls. All antibodies used were purchased from
Santa Cruz Biotechnology.
For measuring secreted TSP4, cells were plated at 2.5×
10
5 per well in a six well plate. Media was changed after
24 h and cells were treated with SHetA2 for different time
points. The media was collected at each time point and an
equal volume of media was used for immunoprecipitation
using TSP4 antibody (Santa Cruz Biotechnology) conju-
gated to protein G agarose. The immunoprecipitates were
run on SDS-PAGE and analyzed by western blot analysis
using TSP4 primary antibody (R&D systems) following
western blot protocol described above.
VEGF and bFGF measurements
Quantikine Human enzyme-linked immunosorbent assay
(ELISA) kits for VEGF-A and bFGF (R&D Systems) were
used to quantify the concentration of VEGF or bFGF in
conditioned media. Absorbance was measured using an
automatic microplate reader at 450 and 540 nm. The
concentration of VEGF-A or bFGF in each sample was
interpolated from the plate specific standard curve after
subtracting the background staining at 540 nm from the
absorbance measured at 450 nm.
Conditioned media
For the conditioned media experiments, epithelial cells
were plated at 400,000 cells per well of 6 well tissue culture
dishes and cultured in the presence and absence of 10 μM
SHetA2 in McCoy’s growth media for the kidney HK-2
normal and Caki-1 cancer and IOSE-80 media for the
ovarian epithelial IOSE-80 normal and A2780 cancer cells.
After 48 h, 1 mL aliquots were removed and centrifuged to
remove cellular debris. The cleared media was immediately
used or cryopreserved at −80°C. For the TP experiments,
recombinant TP (R&D Systems) was added (final concen-
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control solvent only wells. After another 24 h, 1 mL
aliquots of media from the different indicated conditions
were removed and centrifuged to remove cellular debris.
HUVEC endothelial tube formation assay
The endothelial tube formation assay was performed using
the Chemicon in vitro Angiogenesis Assay Kit. Wells in a
96 well plate were coated with ice cold EC Matrix Gel
Solution in the EC Matrix Diluent Buffer. After solidifica-
tion of the matrix at room temperature, HUVEC cells were
seeded onto the polymerized EC Matrix at a concentration
of 10,000 cells in 50 μL of EMB-2 media per well. Fifty
microliters of conditioned media was immediately added
after plating HUVEC cells for a final 1:1 ratio of EMB-2
media to conditioned media. The number of tubule
branches were photographed and counted after 16 h of
incubation. The results from three independent experiments
performed in triplicate were averaged. To study direct
effects of SHetA2 on endothelial tube formation, eight
treatments were performed in duplicate. Four treatments
consisted of 0, 1, 3 or 5 μM of SHetA2 while the remaining
four received these treatments in addition to 125 mg/mL of
TP. After 16 h incubation at 37°C, photomicrographs were
taken and the number of branch tubules were counted. The
results of three experiments performed in duplicate were
averaged.
EAhy.926 endothelial tube formation assay
The endothelial tube formation assays performed with
EAhy.926 cells were performed using a slight modification
of the method published by others [27, 28]. Ninety-six-well
microtiter plates will be coated with 150 μL Matrigel at
4°C and incubated for 30 min at 37°C to allow the gel to
solidify. EAhy.962 were plated onto the Matrigel-coated
wells at a concentration of 10,000 cells per well. The
cultures were immediately treated with 0, 1, 5 or 10 μM
SHetA2 or DMSO solvent control in triplicate in an
arbitrary pattern and grown for 20 h. The wells were
evaluated under a microscope by a person blinded to the
treatment order of the wells and who counted the number
of tube branches. Photomicrographs were taken to record
the characteristics of the cultures under various treatment
conditions.
Cell cycle analysis
HUVECs were plated at 1×10
6 cells per plate and treated
with SHetA2 at 0, 1, 3 and 5 μM in the absence or presence
of 125 mg/mL TP. A parallel set of plates were treated
with DMSO. After 16 and 24 h of incubation, the cells
were washed with PBS, trypsinized and collected in cell
culture medium. Cells were centrifuged, washed with
PBS, and centrifuged again. The cell pellet was resus-
pended in 2 mL PBS and cells were fixed by drop-wise
addition of 5 mL of 100% ethyl alcohol while vortexing.
After incubation overnight at 4°C, the cells were centri-
fuged and washed in PBS, and pelleted again. The cells
were resuspended in 1 mL of staining solution containing
5% TritonX-100, 1 mg/mL RNase and 1 mg/mL propi-
dium iodide (PI) in phosphate buffered saline and allowed
to stained for 3 h in the dark at room temperature. The
samples were then analyzed using a FACSCalibur (Becton
Dickinson) automated benchtop flow cytometer and
quantified using Summit for MoFlo Acquisition and Sort
Control Software (Cytomation).
Apoptosis assay
The Vybrant Apoptosis Assay Kit #3 (Molecular Probes)
was utilized to measure apoptosis and necrosis. Tissue
culture medium in each well was collected to harvest cells
that had already lifted off the tissue culture plate. These
were combined with adherent cells that were harvested by
trypsinization. The cells were pelleted by centrifugation and
resuspended in 100 μL of 1X annexin-binding buffer, and
then incubated with 5 μL of annexin V conjugated to
fluorescein (annexin-V–FITC) and 1 μL of 100 μg/mL PI
dye for 15 min at room temperature. The solution was then
mixed gently with an additional 400 μL of 1X annexin-
binding buffer and the samples were evaluated with Flow
Cytometry at an excitation wavelength was 488 nm and
observation wavelengths of 530 and 575 nm.
Xenograft tumors
Caki-1 xenograft tumors were provided by Melinda
Holingshead, PhD (NCI) from an experiment in which 25
tumor bearing mice were gavaged with polyethylene glycol
(PEG400) and three groups of 15 tumor bearing mice each
were gavaged with 20, 40 and 60 mg/kg/day SHetA2 in
PEG400. Significant effect on tumor size was observed
only in the highest treatment group at 40% reduction in
tumor size. Tumors were fixed in formalin and embedded in
paraffin. Sections (5 μ) of tumor blocks were dewaxed in
xylene, rehydrated in graded ethanol, and washed in water
followed by TBS (50 mM Tris–HCl and 150 mM NaCl, pH
7.4) and stained with hematoxylin and eosin (H&E) and
trichrome for histological evaluation. Immunohistochemical
analysis of TP expression was performed using the TP/PD-
ECGF Ab-1 primary antibody (Labvision) and the Ultra-
Streptavidin Detection System HRP (Signet). After rinsing
in distilled water, sections were counterstained with
hematoxylin.
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Microarray analysis of ovarian cancer organotypic cultures
suggests anti-angiogenesis activity
The first indications that Flex-Het regulated expression of
angiogenic cytokines were observed in microarray analysis.
The biological model used consisted of A2780 ovarian
cancer cells grown in organotypic culture for 2 weeks with
a low dose of SHetA2 (1 μM) or DMSO solvent control.
Histological evaluation of the cultures demonstrated that
both apoptosis and differentiation were induced in the
treated cultures in comparison to the untreated controls
exposed to solvent only (Fig. 1a). Most of the cell clumps
in the treated cultures were undergoing apoptosis with some
cells exhibiting nuclear characteristics of early apoptosis. A
smaller fraction of the clumps in the treated cultures
contained cells that exhibited more differentiated pheno-
typic characteristics. Microarray analysis of RNA isolated
from these cultures identified a total of 44 genes that were
differentially expressed between treated and untreated
sample groups. Out of the 44 selected genes, 21 have
known annotation information and are presented in Table 1.
TP, which encodes a known angiogenic factor, was only
expressed in untreated cells suggesting that repression
of these gene by SHetA2 may lead to anti-angiogenic
activity. SHetA2 repression of TSP-4 however, contradicted
this theory, because it encodes an uncharacterized member
for a family of TSP genes that encode anti-angiogenic
proteins.
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Fig. 1 Differentiation and apoptosis in A2780 organotypic cultures
used for microarrays (a). Twelve A2780 organotypic cultures were
grown in the absence of drug. After 10 days of growth, six of the
cultures were treated with 1 μM SHetA2 and six were treated with the
same volume of solvent. After 2 weeks of treatment with drug or
solvent, one untreated and one treated culture were fixed in formalin,
embedded in paraffin, sectioned and stained with hematoxylin and
eosin (H&E). Photomicrographs representative of the entire cultures
are presented in this figure (×40). The other collagen gels were
digested with collagenase, the cells were pelleted, and the RNA was
isolated for microarray and validation analysis. The arrows point to
nuclei undergoing early apoptosis in both apoptotic clump (A) and
differentiating clump (D). Regulation of TP (b) and TSP-4 (c) mRNA
and protein expression. A2780, SK-OV-3, Caki-1, HK-2, and D1 cells
were treated with the indicated doses of SHetA2 for 24 h or 10 μM
SHetA2 for the indicated amount of time. RNA extracts from A2780
cultures were evaluated using rt-PCR. Protein extracts from the
indicated cell lines were evaluated by Western blot analysis for time–
and dose–response effects on TP expression by SHetA2. TSP-4 was
immunoprecipitated from conditioned media and evaluated by
Western blot
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and normal cell cultures
rtPCR analysis of RNA isolated from A2780 cultures
confirmed that SHetA2 reduced expression of TP mRNA
in a time-dependent manner (Fig. 1b). Down-regulation of
TP protein expression also was observed in A2780 and
SKOV3 ovarian cancer cell lines and the Caki-1 renal
cancer cell line in time-dependent (Fig. 1b) and dose-
dependent (Fig. 1b) manners by Western blot analysis.
Consistent with the differential induction of apoptosis and
upstream events observed for SHetA2 in cancer versus
normal cells [15], TP was down-regulated in cancer cell
lines, but not in normal cultures of kidney tubule epithelial
cells (HK-2 cell line) or primary endometrial cultures (D1)
over a 24-h treatment period (Fig. 1b). Although rtPCR
analysis indicated that TP was not completely eliminated by
24 h of treatment, the trend towards decreasing TP protein
expression observed with time could lead to the lack of
expression after 2 weeks of treatment as observed in the
microarray analysis.
In contrast to the microarray results identifying TSP-4
down regulation by SHetA2, rtPCR demonstrated that TSP-
4 mRNA was up-regulated by SHetA2 in a time dependent
manner (Fig. 1c). This up-regulation was confirmed by
Western blot analysis of immunoprecipitated protein from
Table 1 Differentially expressed genes in organotypic ovarian cancer model of SHetA2-induced differentiation
Function/description Gene ID Untreated Treated Ta Ts Ratio
Ave SD P Ave SD P
A1 Over expressed in treated
FEV protein NM_017521 2.19 0.77 1.20E−08 3.57 0.79 0.00E+00 3.60E−02 4.40E−06 1.63
Endothelial zinc finger protein
induced by tumor necrosis factor a
BC014280 1.84 0.8 4.40E−06 3.14 0.13 0.00E+00 4.90E−02 0.00E+00 1.7
A2 Over expressed in untreated
PRO0618 protein NM_014133 5.45 1.12 0.00E+00 3.62 0.71 0.00E+00 2.90E−02 3.30E−05 0.66
Protease inhibitor 15 NM_015886 5.16 1.15 0.00E+00 3.35 0.72 0.00E+00 3.30E−02 1.30E−05 0.65
CGI-89 protein AL161962 4.95 1.11 0.00E+00 3.24 0.62 0.00E+00 2.80E−02 2.60E−06 0.65
Galactosamine (N-acetyl)-6-sulfate sulfatase NM_000512 4.85 1.28 3.60E−14 2.52 0.41 0.00E+00 9.50E−03 3.80E−15 0.52
Smcx homolog, X chromosome (mouse) NM_004187 4.73 1.15 2.20E−16 2.89 0.59 0.00E+00 2.10E−02 5.10E−07 0.61
Thrombospondin 4 NM_003248 4.69 1.46 1.60E−10 2.73 0.55 0.00E+00 3.90E−02 2.90E−06 0.58
Protein phosphatase 1, regulatory
(inhibitor) subunit 12C
NM_017607 4.44 0.95 0.00E+00 2.6 0.55 0.00E+00 1.30E−02 3.10E−07 0.59
Galactose-4-epimerase NM_000403 3.41 0.76 0.00E+00 2.24 0.43 0.00E+00 3.50E−02 5.10E−05 0.66
Alpha-1-B glycoprotein AK027222 3.18 0.75 0.00E+00 1.78 0.34 0.00E+00 9.50E−03 4.80E−09 0.56
Procollagen-proline, 2-oxoglutarate
4-dioxygenase (proline 4-hydroxylase),
alpha polypeptide II
NM_004199 2.73 1.17 3.30E−06 1.34 0.25 0.00E+00 2.90E−02 1.30E−13 0.49
Dopachrome tautomerase (dopachrome
delta-isomerase, tyrosine-related protein 2)
AJ000503 2.6 0.71 3.00E−13 1.61 0.36 0.00E+00 3.10E−02 4.40E−06 0.62
A3 Only expressed in treated
Bol, boule-like (Drosophila) NM_033030 1.25 0.81 1.90E−03 2.92 1.16 5.10E−07 3.90E−02 8.50E−06 2.33
DNA-binding transcriptional activator NM_006316 1.18 0.62 1.60E−04 2.81 0.89 2.90E−10 1.90E−02 6.40E−10 2.38
A4 Only expressed in untreated
SM-11044 binding protein NM_020123 5.25 1.93 5.30E−08 1.99 1.48 7.00E−03 4.00E−02 4.80E−03 0.38
Thymidine phosphorylase (TP) NM_001953 1.71 0.61 2.60E−08 0.72 0.48 3.00E−03 3.50E−02 2.30E−03 0.42
Transglutaminase 4 (prostate) NM_003241 1.49 0.4 5.60E−14 0.35 0.7 3.20E−01 2.80E−02 3.80E−03 0.24
ARP1 actin-related protein 1 homolog B,
centractin beta (yeast)
NM_005735 1.2 0.46 1.70E−07 0.11 0.22 3.20E−01 1.90E−02 1.30E−03 0.09
M-phase phosphoprotein 6 NM_005792 0.98 0.24 4.40E−16 0.24 0.48 3.20E−01 2.80E−02 4.00E−03 0.24
3-Hydroxyisobutyrate dehydrogenase AK025558 0.84 0.31 5.20E−08 0 0 1.00E+00 1.20E−05 3.80E−41 0
P is probability that the given gene expression is not distinguishable from background. Small P values indicate that gene is distinctive from
background, or in other words “expressed”. Ta is a result of the associative t test in which the replicated residuals for each gene of the experimental
group are compared with the entire set of residuals from the reference group. The null hypothesis (H0) is tested and considered true if gene expression
in the experimental group presented as replicated residuals (deviations from averaged control group profile) is associated with the highly
representative (several hundreds members) normally distributed set of residuals of gene expressions in the reference group. The significance threshold
was corrected to make the appearance of false positive determinations improbable. Ts is the result of the Student t test for replicates
310 Invest New Drugs (2009) 27:304–318conditioned media collected from SHetA2-treated and
control cultures of ovarian cancer (A2780 cell line) and
normal immortalized ovarian cancer cells (IOSE-80) in
time-dependent manners (Fig. 1c). If TSP-4 possesses anti-
angiogenic activity similar to other members of the TSP
family, this up-regulation would be consistent with SHetA2
exerting anti-angiogenesis activity. The differences ob-
served in microarray and rtPCR results may be due to the
different culture formats and incubation times evaluated.
While microarray analysis is used in screening studies to
identify genes involved in biological activities, the high
level of artifact in this experimental format requires
validation of the results. Since rtPCR is a more accurate
technology considered as the gold standard for validation of
microarray results, and Western blot analysis confirmed up-
regulation of TSP-4, it is therefore concluded that TSP-4
expression is increased by SHetA2 treatment.
Evaluation of the effects of SHetA2 on secretion of
angiogenic and anti-angiogenic factors was expanded to
include the well-characterized basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF).
rtPCR analysis demonstrated induction of bFGF mRNA
expression in the A2780 ovarian cancer cell line (Fig. 2a).
Evaluation of altered gene expression also needed to be
evaluated at the cytokine secretion level, because altered
mRNA expression does not always translate linearly with
altered proteinsecretionfromcellsduetomultipleregulatory
steps at the mRNA stability, translational, post-translational
and secretion levels. SHetA2 induction of secretion of bFGF
protein secretion was demonstrated by ELISA analysis of
conditioned media collected from A2780 cultures (Fig. 2a).
This up-regulation however was only observed at concen-
trations greater than 5 μM, while microarray and angio-
genesis experiments presented below were all conducted at
concentrations below 5 μM to avoid induction of apoptosis
that that occurs at higher concentrations.
Although SHetA2 induction of VEGF mRNA expres-
sion was observed in the A2780 cell line by rtPCR, ELISA
of conditioned media demonstrated reduced levels of
VEGF secretion after 8 h of SHetA2 treatment (Fig. 2b).
To determine if inhibition of VEGF secretion was cell line
specific, a series of cancer and normal cultures were
evaluated. ELISA of conditioned media demonstrated
higher levels of VEGF secretion in the cancer cultures
(A2780 ovarian and Caki-1 renal cancer cell lines) in
comparison to the normal cultures (HK-2 normal renal
tubule and D1 primary endometrial cultures). Dose-respon-
sive inhibition of VEGF secretion was exerted by SHetA2
in all cell types evaluated (Fig. 2b) consistent with the
proposed anti-angiogenic activity.
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Fig. 2 Regulation of bFGF and VEGF mRNA and protein expres-
sion. RNA isolated from A2780 cultures treated with 10 μM SHetA2
or solvent for the indicated time was analyzed by rt-PCR for bFGF (a)
and VEGF (b) expression. Results or rtPCR experiments presented are
representative of two independent experiments performed in triplicate.
Media conditioned by incubation with A2780 cultures and other
indicated cultures were evaluated for bFGF (a) or VEGF (b) protein
secretion by ELISA. ELISA results are averages of three independent
experiments performed in triplicate
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versus normal cells
Before Flex-Het effects on secretion of angiogenic factors
from cells could be evaluated, an experimental model with
multiple levels of control was needed. The approach
involved conditioning media by incubation with cultured
cells for 48 h. Angiogenic activity of cell secretions that
accumulated in the conditioned media was quantified in the
endothelial tube formation assay. In this assay, endothelial
cells plated on Matrigel were cultured in a 1:1 mixture of
the endothelial cell growth media to the conditioned media.
The number of endothelial tube branches that formed after
16 h of incubation of triplicate cultures were counted and
compared between different treatments (Fig. 3a–c). The
majority of angiogenic factors present in the media
containing FBS were degraded upon incubation at 37°C
for 48 h as demonstrated by the number of endothelial
tube branches formed in cultures exposed to media that
was freshly removed from 4°C storage in comparison to
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Fig. 3 Regulation of angiogenic factor secretion from epithelial
cultures. The effects of the indicated types of conditioned media on
endothelial tube branches are documented by photomicrographs (a)
and quantification of endothelial branches (b and c). The results from
three independent experiments performed in triplicate were averaged.
Significant differences with P values <0.05 were determined by a two-
tailed t test in b and by ANOVA in c
312 Invest New Drugs (2009) 27:304–318media that had been incubated without cells (compare
“Fresh” with “Inc. w/o Cells” in Fig. 3b). Incubation of
the media with Caki-1 renal cancer cells however
generated conditioned media that had similar angiogenic
a c t i v i t yt ot h ef r e s hm e d i a( F i g .3b). Conditioned media
from HK-2 normal cell cultures did not exert angiogenesis
activity (Fig. 3b). A similar pattern of angiogenesis
activity secretion from cancer and not normal cultures
was observed when A2780 ovarian cancer cells and IOSE-
80 ovarian normal cells were compared (Fig. 3c). To avoid
artifacts caused by different media formulations, identical
media was used for each set of cancer and control cultures:
McCoy’s growth media for Caki-1 cancer and HK-2
normal kidney cultures, and IOSE-80 growth media for
A2780 cancer and IOSE-80 normal ovarian epithelial
cultures.
SHetA2 inhibition of secretion of angiogenic cytokines
and promoting activity
In evaluating the effects of SHetA2 on secretion of angio-
genic factors from the epithelial cultures it is important to
control for potential direct effects on endothelial cells by
residual SHetA2 drug remaining in the media after
conditioning. Therefore, conditioned media were compared
to media that were incubated with the same drug and time
frame in the absence of cells. Comparison of the −SHetA2
and +SHetA2 bars Fig. 3b, demonstrates that the residual
SHetA2 remaining in the media incubated without cells had
no effect on the number of branches formed. The ability of
Caki-1 cancer cells to restore incubated media to the level
of angiogenesis activity exhibited by fresh media that was
observed in Fig. 3b, was significantly reduced by SHetA2
treatment (Fig. 3b; two-tailed t test P=0.001). This inhibitory
activity of SHetA2 on angiogenic cytokine secretion from
cancer cells could be counteracted by replenishing the media
with exogenous recombinant TP for both renal and ovarian
cancer cells (Fig. 3c). VEGF could not be evaluated in this
manner because it is an essential component of the
endothelial tube formation assay.
Direct action of Flex-Het on endothelial cell tubule
formation
The ability of SHetA2 to directly affect HUVEC cells and
immortalized endothelial Eahy.923 cells was evaluated in
the endothelial tube formation assay. A dose-responsive
inhibition of endothelial vascular tube branching was
caused in both cell types by SHetA2 treatment (Fig. 4a,b).
The EAhy.926 cells formed thicker tubules, possibly due to
the fused carcinoma component of this cell line (Fig. 4a).
SHetA2-treated EAhy.926 tubules developed increased
thickness at 1 μM and increasing proportions of solitary
clumps of cells at 5 and 10 μM indicated that SHetA2
may be inhibiting endothelial cell migration. Although ad-
dition of exogenous recombinant TP to the culture media
slightly decreased tubule branching in the absence of
SHetA2, recombinant TP treatment was able to attenuate
the SHetA2 inhibition of endothelial tubule branching
(Fig. 4b).
Induction of endothelial cell G1 phase cell cycle arrest,
but not apoptosis
Since SHetA2 is known to induce cell cycle arrest at
concentrations below 5 μM and apoptosis at concentrations
above 3 μM, HUVEC cells were evaluated with flow
cytometry for cell cycle and apoptosis response to SHetA2
treatment. SHetA2 at concentrations ranging from 1 to
5 μM induced G1 cell cycle arrest after 16 h (data not
s h o w n )a n d2 4ho ft r e a t m e n t( F i g .4c). The G1 arrest
could not be prevented by exogenous recombinant TP
treatment, suggesting that inhibition of TP is not involved
in the mechanism of cell cycle arrest (Fig. 4c). Early apo-
ptosis was not induced by 1 to 5 μM SHetA2 in HUVEC
cells, but necrosis (which cannot be differentiated from
late apoptosis in this assay) appeared to be induced
slightly at 5 μM( F i g .4d). Exogenous TP did not regulate
apoptosis in the absence or presence of SHetA2 (Fig. 4d).
There were no statistically significant differences between
the numbers of live, early apoptosis or late apoptosis/early
necrosis in the different treatment groups, as evaluated by
ANOVA or by two-tailed t tests.
Regulation of angiogenic cytokines in HUVEC cells
rtPCR analysis revealed a time-dependent induction of TP
mRNA after 8 h of treatment with 5 μM SHetA2 (Fig. 5a).
Late upregulation of TP protein expression was confirmed
by Western blot analysis after 24 h (Fig. 5b). A gradual
increase of VEGF mRNA was consistent with increased
VEGF protein secretion (Fig. 5c,d). The bFGF cytokine
was unaltered by SHetA2 treatment of HUVEC cultures
(Fig. 5d).
Inhibition of angiogenesis in vivo
Potential SHetA2 anti-angiogenesis activity in vivo was
evaluated in H&E stained sections of Caki-1 xenografts
from an animal model conducted by the NCI RAID
program in which 40% reduction of xenograft tumor size
was induced by SHetA2 (Fig. 6a). Pathology review of the
H&E stained sections revealed that the carcinoma was
invading the venous system and causing massive backup of
blood and necrosis that is hemorrhagic. Figure 6a right
hand panel shows a dilated blood vessel in the midst of a
Invest New Drugs (2009) 27:304–318 313large area of necrosis. The SHetA2-treated tumors exhibited
an ischemic type necrosis with little or no blood, which is
known to occur when the blood supply is interrupted.
Trichrome stain was used for better visualization of tumor
vessels (Fig. 6b). The untreated tumors demonstrated a
certain degree of vascular organization where blood vessels
penetrate the tumor from the edge and go toward the center.
In general, smaller blood vessels extended from larger
vessels and travel parallel to the tumor surface. In contrast,
SHetA2 treated tumors show marked vascular disorganiza-
tion. There was a greater amount of necrosis in areas not
nourished by vessels and many necrotic areas that have
blood vessels running through. TP staining of the Caki-1
xenograft sections demonstrated an increased expression
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Fig. 4 Direct regulation of endothelial tube branching. Photomicro-
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314 Invest New Drugs (2009) 27:304–318of TP protein in all of the treatment groups (Fig. 6c). This
was confirmed by Western blot analysis of tumor extracts
(Fig. 6d).
Discussion
The results of this study demonstrate that the lead Flex-Het,
SHetA2 exerts anti-angiogenic activity at multiple levels.
Intracellular communication through secretion of cytokines
represents the primary mechanism by which tumors recruit
developing blood vessels. The inhibition of secretion of
angiogenesis activity from cancer cell cultures by SHetA2
appears to be due to effects on several specific cytokines.
The SHetA2 down-regulation of TP mRNA and protein
was found to occur in cancer, but not normal cells and
therefore may be related to the mechanism of differential
induction of apoptosis. TP-catalyzed nucleotide salvage is
an essential component of cellular and mitochondrial DNA
replication and cell survival. TP and the 2-deoxy-D-ribose
metabolite can inhibit intrinsic mitochondrial-driven apo-
ptosis induced by hypoxia [19]. Therefore, the TP reduction
by SHetA2 may be involved in the mechanism by which
this drug induced the intrinsic mitochondrial apoptosis
pathway [11, 15]. Although angiogenesis effects of TSP-4
have not yet been characterized, the presence of type III
repeats, similar to the anti-angiogenic modules present in
TSP-1 [22], suggests that TSP-4 is likely to be anti-
angiogenic. Thus, SHetA2 up-regulation of TSP-4 mRNA
and protein secretion is consistent anti-angiogenic activity.
Although VEGF mRNA was induced twofold, by SHetA2,
the ultimate outcome of treatment across all normal and
cancer cell lines tested was an inhibition of VEGF pro-
tein secretion, consistent with anti-angiogenic activity. The
SHetA2 up-regulation of bFGF may not be severely in-
terfering with the net anti-angiogenic effect because it is
not up-regulated until after hours of treatment and only
at high concentrations that can only be briefly achieved
in vivo [29].
The process of developing and maintaining tumor blood
vessels is controlled by a balance of pro- and anti-
angiogenic factors. Our hypothesis that the net effect of
SHetA2 on this balance would be to reduce angiogenesis
activity secreted from cancer cells was supported by
SHetA2 reduction of angiogenesis stimulating activity in
conditioned media from cancer cells. The role of TP in this
net effect was supported by the partial reversal of this
reduction upon addition of exogenous recombinant TP.
Since TP has no known transcriptional regulatory activities,
but plays a critical role in mitochondrial function [30], the
mechanism by which TP attenuates SHetA2 reduction of
angiogenic secretion is most likely through interference
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Fig. 5 Regulation of angiogenic cytokines in HUVEC cultures.
HUVEC cultures were treated with 5 μM or the indicated doses of
SHetA2 for 24 h. RNA isolated from the cultures was evaluated for
expression of TP (a) and VEGF (c) mRNA using rt-PCR. Results
represent the average and standard error of three independent experi-
ments performed in triplicate. Protein extracts were evaluated by
Western blot analysis for TP expression (b). Western blot results
represent the average and standard error of two independent experi-
ments. Data from one experiment was multiplied by a factor of 2 to
normalize the results to the second experiment for presentation on a
single graph. Conditioned media was evaluated by ELISA for VEGF
expression (d). ELISA results represent the average and standard error
of three independent experiments performed in triplicate
Invest New Drugs (2009) 27:304–318 315with SHetA2 mitochondrial alterations [15]. SHetA2
regulation of the cytokines at the mRNA level, suggest
that this drug may exert activities through transcriptional
regulation. Preliminary data indicate that SHetA2 regulates
gene expression through the nuclear factor kappa B (NF-κ)
transcription factor pathway [31, 32].
The hypothesized direct effect of SHetA2 on endothelial
cells was supported by the dose-dependent inhibition of
endothelial tube formation in an in vitro assay. While the
induction of G1 cell cycle arrest by SHetA2 on endothelial
cells is likely to contribute to the mechanism of action
inhibiting endothelial tube formation, it is not likely to be
primarily responsible. This is because the G1 cell cycle
arrest was not prevented by exogenous TP, while the
endothelial tube formation was counteracted by TP. Also,
the G1 arrest is induced in both cancer and normal cultures
by SHetA2, while regulation of apoptosis and TP expres-
sion by SHetA2 occurs with a strong differential effect on
cancer cells over normal cells. Necrosis or apoptosis are not
likely to contribute to the mechanism by which SHetA2
inhibits endothelial tubule formation because only at
concentrations above that used in the tubule assay are able
to induce a slight increase in necrosis/apoptosis in
endothelial cells.
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Fig. 6 In vivo regulation of angiogenesis in Caki-1 xenograft tumors.
H&E stained sections (a) demonstrate hemorrhagic necrosis in tumors
for the untreated control group and ischemic necrosis in the tumors from
the group gavaged with 60 mg/kg/day SHetA2. The photographs of
untreated tumors show the carcinoma invading the venous system and
causing massive backup of blood and necrosis that is hemorrhagic. The
last photo of this panel shows a dilated blood vessel in the midst of a
large area of necrosis. The photographs of the treated tumors show an
ischemic type necrosis with little or no blood. This is caused by the
blood supply being interrupted and occurs almost totally in the treated
animals. Trichrome staining in of the sections (b) shows blockage and
increased disorganization of blood vessels in the treated tumors in
comparison to the controls. In untreated tumors, there is a certain degree
of vascular organization where blood vessels penetrate the tumor from
the edge and go toward the center. In general, smaller blood vessels
extend from larger vessels and travel parallel to the tumor surface. In
SHetA2 treated tumors show marked vascular disorganization. There is
a greater amount of necrosis in areas not nourished by vessels and many
necrotic areas that have blood vessels running through. Immunohisto-
chemical analysis of TP expression (c) documents up-regulation of TP
expression at the end of the 30-day treatment period. Western blot
analysis of protein extracts taken from the tumors (d)c o n f i r m st h eT P
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316 Invest New Drugs (2009) 27:304–318The induction of TP expression in endothelial cells is in
contrast to the down-regulation of this protein in multiple
cancer cell lines. Increased TP mRNA is not observed in
endothelial cells within the first 8 h of treatment indicating
that it is a late responding event. The ultimate outcome on
endothelial tube formation however is inhibition, and the
endothelial attempt to counteract this inhibition by increased
TP expression does not appear to be able to counteract
SHetA2 effects in vitro or in vivo.
SHetA2 inhibition of angiogenesis in vivo was con-
firmed in histologic evaluation of Caki-1 renal cancer
xenografts. The 40% reduction in tumor size induced by
SHetA2 in this animal model (Liu et al. 2008, in
preparation) was associated with alterations in blood
vessels. Necrosis occurred in tumors from both untreated
control and SHetA2-treated animals. The type of necrosis in
the untreated controls was associated with tumor cell
invasion of blood vessels causing hemorrhage, while the
type of necrosis that occurred in the tumors from treated
animals was associated ischemia apparently due to lack of
oxygen. This hypoxia appeared to be due to interference of
the blood supply through blockage of the blood vessels
causing swelling of the vessels and necrosis of the tumor
cells within a short distance of the blood vessels. The dose-
dependent up-regulation of TP in the tumors was confirmed
by Western blot analysis. A time-dependent experiment is
planned to test the hypothesis that this up-regulation is a
late response to hypoxia induced by SHetA2 inhibition of
angiogenesis.
The results of this study demonstrated in vitro and in
vivo anti-angiogenesis activity of SHetA2 through reduc-
tion of cancer cell secretion of angiogenic activity and
through direct effects on endothelial cells. Reduction of the
pro-angiogenic cytokines, TP and VEGF, and induction of
the potential anti-angiogenic cytokine TSP-4, appear to be
involved in the mechanism. The response of endothelial
cells to SHetA2 anti-angiogenesis appears to involve up-
regulation of TP expression in vitro and in vivo. The
complexity of angiogenesis regulation by SHetA2-induced
alterations in the balance of pro- and anti-angiogenic factors
will require a systems biology approach to provide
sufficient understanding of the angiogenesis regulation to
appropriately design planned clinical trials.
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